Camlin Fine Sciences Ltd Q3 FY26 Earnings Analysis

- Vanillin sales expected to reach about 4,000 tons next year. - Blends business targeted to grow by 20% next year. - Overall blends business projected to grow by 18%-20% year-on-year, supported by field force expansion and inorganic growth (new acquisition in France). - Field force expanded by 21%, with impact expected to start from Q4 FY'26 and continue into next year. - Incremental EBITDA expected from diphenol facility ramp-up, currently at ~50%-55% utilization, aiming for full capacity with cost advantages. - Sales growth for blends and vanillin on track despite tariff pressures and global uncertainties. - Contract wins for H1 of next calendar year, indicating visibility on volumes and prices. - Market de-stocking expected to complete by Q4 FY'26 in US and Q1 FY'27 in Europe, supporting volume growth.

- The company expects 20% growth in the Blends business next year, supported by a 20% increase in salesforce and inorganic growth from acquisitions. - Vanillin sales guidance is about 4,000 tons for the next year, with anticipated EBITDA improvement as diphenol facility utilization increases from current 50-55% to full capacity. - Full capacity utilization of the diphenol facility (~6,000 MT) will reduce costs from $9.5-$10/kg to $8/kg, positively impacting margins and earnings. - EBITDA margin is expected to improve with higher capacity utilization and potentially lower tariffs. - European discontinued operations losses (~Rs. 25 crores annually) are expected to reduce to about Rs. 8 crores annually from FY'27 onwards. - Employee cost increases due to expanded sales force are anticipated but are aligned with revenue growth plans. - Overall, the company projects a positive earnings trajectory as tariff impacts ease and channel inventories clear by Q4 FY'26 and Q1 FY'27 in key markets.

- No significant fixed asset expenditure apart from maintenance-related spends in the recent period. - Gross debt situation has remained stable, with some loan repayments balanced by working capital needs due to revenue growth. - Growth-related debt is expected to remain at the same level going forward. - Management highlighted ongoing additions of field force and potential inorganic growth through acquisitions (e.g., acquisition in France to become a subsidiary this quarter) to support blended business growth. - No explicit mention of large-scale future capital investment projects was made in the transcript. The focus appears to be on operational scaling, workforce expansion, and integrating acquisitions rather than on major capex. - Liquidation proceedings initiated for discontinued businesses (e.g., China) to cut down costs, reducing future capital deployment in non-core areas.

- No significant new fixed asset expenditure planned except maintenance. - Gross debt remained stable around Rs. 640-645 crores. - Some loan repayments were done, but working capital needs led to net debt increase from Rs. 490 crore to Rs. 520 crore. - Right issue money has been utilized already. - Overall, growth debt is expected to remain at the same level. - No explicit mention of any new fundraising through debt or equity in the call. - The company appears focused on stable debt levels and organic growth without immediate plans for new equity or significant incremental debt.

- Specific details regarding the current or expected order book or pending orders for Camlin Fine Sciences Limited were not explicitly disclosed during the call. - Contracts for Vanillin for H1 calendar year 2027 have been signed, indicating some visibility into the near-term order book at prevailing prices (around $19.5 DDP). - Contracts are generally for one or two quarters rather than full-year contracts due to current market uncertainties and existing channel stocks. - The company noted winning some contracts for the first half of next year, reflecting a moderate order pipeline amid tariff and market challenges. - Demand is cautiously monitored given over-inventories in US and Europe; full clarity awaits tariff resolution and inventory normalization. - The mix of CIF and DDP contracts affects timing and realization of tariff benefits on orders. - No quantified pending order book figures were shared during the discussion.